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1. INTRODUCTION
1.1 HIV life cycle
The Human Immunodeficiency Virus (HIV) is a retrovirus identified as the causative
agent of one of the most devastating infectious diseases that has emerged in recent
history: the Acquired Immune Deficiency Syndrome (AIDS) (45). HIV is comprised of a
number of unique aspects that allows it to escape from the host immune system,
making it a very successful pathogen.
HIV begins its replication cycle by binding to the target cell through two viral
glycoproteins, gp120 and gp41. gp120 recognizes two host proteins: CD4, the receptor,
and either CXCR4 or CCR5, the co-receptor. Following co-receptor binding, gp41
undergoes a conformational change, triggering membrane fusion and allowing the
delivery of the viral capsid into the host cell cytoplasm (54). As soon as the viral capsid
enters the cell, an uncoating process occurs and the viral reverse transcriptase
transcribes the viral RNA genome into double-stranded cDNA. The newly formed cDNA
associates with viral and cellular proteins, ill-defined, forming the pre-integration
complex (PIC) (24). The PIC is then transported into the nucleus assisted by several
viral proteins including Vpr, Vif, and p17, that interact with the host nuclear import
machinery (28). Once the PIC is located in the nucleus, the viral integrase catalyzes the
insertion of the linear double-stranded viral DNA into the host cell chromosome. The
integration step is absolutely required for HIV viral replication (14). After integration, the
viral LTR serves as a promoter to initiate the transcription of HIV-DNA into mRNA that
will subsequently be translated into proteins needed for HIV progeny formation. The
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viral proteins and the genomic RNA interact to form virions in a process called
assembly, in which participate several proteins of the multivesicular body vesicle
budding system (48). The newly formed virions then bud out of the cell, crossing the
plasma membrane, and shortly after the capsid proteins undergo extensive viral
protease-mediated processing forming as a result mature virions (48).
1.1.2 Integration: essential step in HIV-replication
The integration of the viral DNA into the host chromosome is a fundamental step in
the HIV replication cycle (14). The integration process is mediated by the viral protein
integrase (IN), which enters the cells in the incoming virion and persist associated to the
reverse transcription complex (RTC) and later to the PIC (14). Once the viral DNA has
been synthesized, integrase catalyzes the removal of two nucleotides from the 3’ termini
(3’ end processing), and the processed viral DNA is then imported into the nucleus
where the integration process occurs (14). Integrase also catalyzes a second reaction
referred to as DNA-strand transfer. In this process, the 3’ end of the viral DNA migrates
to the DNA target interrupting the phosphodiester bonds. This results in the 3’ ends
covalently attached to the 5’ ends of the host cell DNA. Then, not-well defined cellular
DNA repair enzymes seal the gaps between the 5’ end of the viral genome and 3’ end
of the cellular DNA (14).
Previous studies have revealed that HIV integrase does not carry out viral DNA
integration alone; rather it uses the cellular machinery to accomplish a successful viral
integration(14). One of the best-characterized cellular factors for HIV-DNA integration is
the Lens Epithelium-Derived Growth Factor /p75 (LEDGF/p75) (32). Although a set of
other cellular proteins including Nucleoporin 153, BAF, HMGA, HMGB, Ini-1, YY1, EED,
	
  
2	
  
	
  
	
  
	
  

	
  
	
  
SUV39H1, and HP1γ have been proposed to contribute to this process, the biological
importance of these proteins in HIV integration remains unclear (14).
HIV DNA integration does not occur randomly in the host genome (10). Several
studies have shown that integration is strongly favored inside transcriptionally active
genes (9-12, 43). This vias in integration site distribution could favor active transcription
of the provirus.
Despite the fact that viral DNA integration is the only nuclear fate of HIV DNA leading
to productive infection, there are other paths that it can follow once it has reached the
nucleus. The viral genome can experience several circularization reactions forming 1- or
2-long terminal repeat (LTR) circles. Since these LTR circles represent non-integrated
HIV DNA, their production does not support HIV replication (14). In addition, nonintegrated viral DNA is degraded in the nucleus by ill-defined mechanisms.
1.2 Cellular roles of LEDGF/p75.
Different cellular functions have been attributed to LEDGF/p75 since its discovery in
1998 (31). Initially, two splice variants were identified for the Psip1 gene, and named
LEDGF/p75 and p52. Both were discovered to be involved in transcriptional coactivation due to their strong interaction with the functional activation domain of several
transcription factors and a number of members of the basal transcriptional machinery
(19, 20). Overexpression of LEDGF/p75 in mouse lens epithelial cells conferred
resistance to thermal and oxidative stress. This protective effect of LEDGF/p75 was
proposed to be determined by the ability of this protein to upregulate specific genes that
control cellular stresses (47). This hypothesis was further supported by the observation
that LEDGF/p75 binds to promoters of stress related genes enhancing their
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transcription. Among these genes is the heat shock protein 27 (Hsp27), which is
involved in protecting cells from damage produced by environmental stresses (37).
Importantly, SUMOylation of LEDGF/p75 and p52 was found to regulate the
transcriptional effects of these proteins on the Hsp27 promoter (5).
More recently, LEDGF/p75 has been linked to cancer. Several NUP98 (nuclear pore
protein 98)-LEDGF fusion proteins, produced by chromosomal translocation of the
NUP98 gene, have been associated to different forms of leukemia (1, 21, 26, 40, 41,
58). Although it is still unclear how LEDGF/p75 can promote oncogenesis, a molecular
role of LEDGF/p75 in leukemogenesis involves the LEDGF/p75-mediated chromatin
tethering of the transcriptional regulator MLL/menin protein complex to Hox genes (58).
The role of LEDGF/p75 in the regulation of Hox genes, which are also known to be
involved in the vertebrate body development during embryonic growth, explains the
severe skeletal abnormalities found in the Psip1 gene knockout mice (49). Furthermore,
LEDGF/p75 has been found to behave as an oncogene since it has been reported to be
overexpressed in many solid tumors and cancer cell lines (3).
In addition to its function in the response to cellular stress and in transcriptional
regulation of specific genes, the molecular mechanisms of LEDGF/p75 in oncogenesis
could also implicate its roles in cell cycle regulation and DNA repair processes.
LEDGF/p75 interacts with a heterodimeric S-phase kinase Cdc7-ASK in human cells.
Cdc7 is a kinase required for DNA replication throughout S-phase of the cell cycle,
whereas its regulatory subunit ASK (activator of S-phase kinase) is essential for its
activation. The Cdc7-ASK complex was found to phosphorylate LEDGF/p75 only in Sphase, which results in the stimulation of the enzymatic activity of Cdc7-ASK in vitro
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(25). Moreover, LEDGF/p75 tethers the DNA repair protein CtIP (C-terminal interacting
protein) to the chromatin in a DNA damage-dependent manner. Upon DNA damage,
LEDGF/p75 tethers CtIP to specific regions of chromatin including sites of dense
histone di and tri-methylation (H3K36); thereby allowing its accessibility to double-strand
breaks in actively transcribed genes. As a consequence, LEDGF/p75 has an active role
in the DNA repair of transcriptionally active genes (15). These findings also suggest that
LEDGF/p75 could recruit CtIP to the HIV DNA integration reaction favoring postintegration DNA repair.
Additionally to the aforementioned roles of LEDGF/p75, other investigations have
implicated this protein in autoimmunity, cell differentiation, apoptosis and to interact with
other cellular proteins like Sp1, PC4, ASF/SF2, JPO2, and PogZ (31). However, the
significance of these interactions in the cellular functions of LEDGF is currently
unknown.
1.3 Role of LEDGF/p75 in HIV infection
In addition to the cellular roles described above, LEDGF/p75 is also implicated in
lentiviral replication by two different mechanisms: allowing efficient HIV DNA integration
and optimizing HIV DNA integration target site selection (31).
LEDGF/p75 was initially shown to interact with HIV integrase in a proteomic
analysis that was intended to discover integrase-binding proteins (7). This interaction
caused an increase in the catalytic activity of integrase in vitro, as well as the prevention
of its degradation by the proteasome (7, 30). These data suggested the participation of
LEDGF/p75 in the HIV DNA integration process. Subsequently, short hairpin RNA
(shRNA) knockdown of LEDGF/p75 showed a fundamental role of this protein in HIV
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integration (32). Cells lacking the expression of LEDGF/p75 displayed a severe
impairment in HIV infection in vitro. Quantitative real-time PCR analysis of the HIV-life
cycle determined that the defect of HIV infection in cells lacking LEDGF/p75 is due to a
failure of HIV DNA integration (32). The molecular mechanisms proposed for
LEDGF/p75 in HIV infection indicated that LEDGF/p75 simultaneously interact with the
host chromatin and with the HIV PIC associated-IN. In this interaction, LEDGF/p75 acts
as a molecular tether that attracts the PIC to the host chromatin allowing HIV-DNA
integration (34). Chromatin binding of LEDGF/p75 is mediated by the functional
interaction of the PWWP and A/T-hook domains located in the N-terminal region of this
protein, whereas interaction with HIV integrase is facilitated by the integrase-binding
domain (IBD) situated in the C-terminal region of the cellular protein (Fig. 1) (34).
In addition to facilitating HIV DNA integration, LEDGF/p75 also contributes to HIV-DNA
target site selection (12, 36). Studies mapping integration site distributions in the
presence or absence of LEDGF/p75 revealed that in cells expressing LEDGF/p75, HIV
preferentially integrate in active transcriptional units within the host genome, while in
LEDGF/p75 depleted cells this integration vias greatly diminishes and HIV exhibited a
more recurrent integration in sequences rich in C/G content and near CpG islands.
These findings highlight the importance of LEDGF/p75 in tethering HIV IN to regions in
the chromatin that ensure effective viral gene expression.
The importance of the LEDGF/p75-IN interaction in the HIV replication cycle
underlines the possibility of designing new anti-HIV therapeutic drugs that interrupt this
protein interaction. Recently, a new class of antiviral agents, 2-(quinolin-3-yl) acetic acid
derivatives (LEDGINs), that effectively block HIV integration was reported (8, 35).
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LEDGINs block the catalytic activity of integrase in an allosteric manner by binding to
the LEDGF/p75-binding pocket of integrase and not to the active site of the viral
enzyme as other anti-HIV integrase drugs do (8).

Figure 1. Protein domain structure of LEDGF/p75. LEDGF/p75 binds to chromatin through
the functional interaction of the PWWP domain and two AT hook motifs located in the N-terminal
region. The integrase-binding domain (IBD), that interacts with several cellular proteins and also
HIV IN is located in the C-terminus of LEDGF/p75. Different polar and evolutionarily conserved
regions (CR) have been defined in this protein.

1.4 Post-translational modifications in LEDGF/p75
Post-translational modifications (PTMs) of proteins are covalent modifications of
amino acids through the addition of functional groups or proteins, and the proteolytic
cleavage of proteins regions (44, 53). Among the best-characterized PTMs are:
phosphorylation,

acetylation,

methylation,

glycosylation,

SUMOylation

and

ubiquitination. The wide diversity of functions that are attributed to a single protein is in
part given by these chemical modifications that a protein can experience. PTMs can
regulate the activity and localization of proteins, as well as their interaction with cellular
molecules and cofactors, resulting in the regulation of cellular activity (44, 53).
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Two PTMs, phosphorylation (4, 13, 17, 22, 29, 38, 39, 46, 50-52, 57) and
SUMOylation (6), have been identified in LEDGF/p75. Phosphorylation is the beststudied PTM, which is involved in many cellular processes including enzymatic activity
activation, inactivation, cell cycle, growth, apoptosis, and modulation of signaling
pathways (44). Different types of protein kinases carry out phosphorylation by adding an
inorganic phosphate group to a protein, principally to serine, threonine, tyrosine, or
histidine residues (44). This process is also reversible, since phosphatases can
dephosphorylate the modified proteins.
In different phosphoproteomic analysis of human and mouse cells, LEDGF/p75 has
been recurrently found to be phosphorylated at multiple residues (4, 13, 17, 22, 29, 38,
39, 46, 50-52, 57). Particularly interesting, a cluster of phosphoserine residues (aa 271,
273 and 275) located in CR3 (Fig. 1) was found to have a role in the HIV cofactor
activity of LEDGF/p75 (18). Similarly, deletion of CR1, a region rich in phosphorylated
residues, also impairs the HIV cofactor activity of LEDGF/p75 (18). However, the role of
the phosphorylated motifs included in CR1 in the HIV cofactor activity of LEDGF/p75 is
still not defined and it will be one of the specific aims of this thesis.
SUMOylation is the reversible, covalent linkage of a Small Ubiquitin-related Modifier
(SUMO) molecule at a lysine residue of a protein (23). SUMO is a member of the
ubiquitin-like proteins that are only present in eukaryotes (55). Different SUMO proteins
have been identified (SUMO 1, 2, 3, and 4) in mammalian cells, and recent
investigations showed distinguishable functional differences between them. The
enzymatic mechanism of SUMO conjugation to different protein motifs is very similar to
ubiquitination and it functions by modifying substrates, changing their molecular
	
  
	
  
	
  

8	
  
	
  

	
  
	
  
interactions, stability, localization, and activities of the target proteins (55).
Maturation is the first step in the SUMOylation process and it involves the cleavage of
the SUMO protein to produce a carboxyl-terminal di-glycine motif. Afterwards, the
SUMO-activating enzyme SAE1/SAE2 (E1) activates SUMO in an ATP-dependent
manner, followed by the transference of the activated SUMO to the SUMO-conjugating
enzyme Ubc9. Finally, SUMO is ligated to the target protein (23).
LEDGF/p75 was initially predicted to be SUMOylated at multiple residues by
bioinformatic analysis. Using a panel of LEDGF/p75 mutants it was experimentally
defined that LEDGF/p75 is SUMOylated at lysine residues K75 (PWWP domain), K250,
K254 (CR2), and K364 (IBD) (5). LEDGF/p75 SUMOylation negatively affects its
transcriptional activity (5), being K364 the main residue implicated in this negative effect
of SUMOylation (27). Importantly, the role of SUMOylation in the HIV cofactor activity of
LEDGF/p75 is unknown and it will be one of the major goals of this thesis.
1.5 Role of PIAS 1 and PIAS 4 in HIV infection (unpublished data)
Protein Inhibitors of Activated Stats (PIAS) are commonly identified as negative
regulators of the cytokine signaling pathway. Moreover, it has also been shown that
PIAS proteins act as an E3-like ligase, facilitating SUMOylation of target proteins
operating in different pathways.
Our laboratory has recently discovered a role for the E3 SUMO-protein ligases PIAS
1 and PIAS 4 in HIV infection (Fig. 2) (Z. Martinez and CS. Seong unpublished data).
PIAS 1 and PIAS 4-deficient cell were shown to have a decreased susceptibility to HIV
infection in single-round infection assays (Fig. 2A). Importantly, the interaction of PIAS
1 and PIAS 4 with LEDGF/p75 was evidenced in a yeast two-hybrid screening also
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performed in our laboratory. However the implication of LEDGF/p75 SUMOylation in the
observed role of PIAS proteins in HIV infection is unknown and will be determined in
this thesis.

B

A

70 kDa

55 kDa

55 kDa

55 kDa

120

KD
PIAS 1

Infectivity (%)

WT

Alpha tubulin

PIAS 4

100

1 Scr (n=2)

80
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3 PIAS 4 KD (n=2)

60
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0
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Figure 2. HIV infectivity of PIAS 1 and PIAS 4-deficient cell lines. (A) The expression of
PIAS 1 and PIAS 4 in the cell lines evaluated in panel B was measured by immunoblotting.
Levels of alpha tubulin are also shown as loading controls. (B) CD4+T cells deficient either for
PIAS 1 or PIAS 4 were infected with a single-round infection HIV reported virus expressing
luciferase. Levels of luciferase were measured five days after infection. These data is
representative of two independent infection experiments.
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2. SIGNIFICANCE
Two regions of LEDGF/p75, the chromatin-binding domain (PWWP and the AT hook
motifs) and the integrase-binding domain (IBD), are required for its HIV cofactor activity
(32) whereas a phosphoserine cluster in CR3 (aa S271, S273 and S275) and CR1
notoriously influence the HIV cofactor activity of this protein (18). However, the
contribution of PTMs to the HIV cofactor activity of LEDGF/p75 remains to be
elucidated. These PTMs in LEDGF/p75 could be involved in recruiting cellular cofactors
implicated in HIV DNA integration. Determining the role of these regulatory circuits in
LEDGF/p75 will not only expand our knowledge on the mechanism of LEDGF/p75 in
HIV DNA integration, but also will offer new opportunities for pharmacological blockage
of HIV infection and potentially for the regulation of genes involved in leukemogenesis
or cell survival.
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3. SPECIFIC AIMS
This thesis includes three different specific aims that focus on understanding the role
of PTMs and the CR6 region of this protein in the HIV cofactor activity of LEDGF/p75:
Specific aim 1. To evaluate the role of SUMOylation in the HIV cofactor activity of
LEDGF/p75. We will generate SUMOylation-deficient mutants by introducing K to R
point mutations in the SUMOylation target sites of LEDGF/p75, express these mutants
in LEDGF/p75-deficient cells, and use the engineered cells in HIV single-round infection
assays. Using this approach We will (1.1) determine whether or not SUMOylation is
required for the HIV cofactor activity of LEDGF/p75. We will also characterize by realtime PCR analysis the HIV life cycle in LEDGF/p75-deficient cells expressing a
LEDGF/p75 SUMOylation-deficient mutant. Furthermore, (1.2) we will assess the
interaction of LEDGF/p75 SUMOylation mutant with HIV integrase by biochemistry
methods. Finally, (1.3) the ability of this mutant to tether integrase to the chromatin will
be evaluated by cell biology techniques.
Specific aim 2. To determine the role of CR1 phosphorylated residues in the HIV
cofactor

activity

of

LEDGF/p75.

LEDGF/p75-deficient

cells

expressing

CR1

phosphorylation mutants will be used as targets in single-round infectivity assays to
(2.1) evaluate the role of CR1 phosphorylation in the HIV-cofactor activity of
LEDGF/p75. Then, (2.2) analysis of the HIV life cycle in LEDGF/p75-deficient cells
expressing a LEDGF/p75 CR1 mutant will also be performed.
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Specific aim 3. To define the role of the CR6 region in the HIV cofactor activity of
LEDGF/p75. In this last specific aim, We will investigate (3.1) whether or not CR6 is
involved in the HIV cofactor activity of a LEDGF/p75 and, if it is involved, (3.2)
characterize the HIV life cycle in LEDGF/p75-deficient cells expressing a LEDGF/p75
ΔCR6 mutant.
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4. MATERIALS AND METHODS
4.1 Plasmids
Stable expression of LEDGF/p75 WT or mutants was achieved by retroviral
transduction. C-terminally FLAG-tagged LEDGF/p75 was expressed from the murine
leukemia virus (MLV) expression plasmid pJZ308 (32). LEDGF/p75 mutants were
generated by PCR with the Phusion™ Site-Directed Mutagenesis Kit (Finnzymes, Inc)
using specific primers (primers sequence available upon request) and following the
manufacturer’s instructions. The LEDGF/p75 cDNA expressed containing seven
synonymous

mutations

in

the

target

site

of

the

twenty-one

shRNA

1340

(AACGGCAACACGAAGAGGCAA, changed nucleotides are underlined) (33). This
shRNA is present in all the LEDGF/p75-deficient cell lines used in this thesis. All the
constructs described above were verified by overlapping DNA sequencing of the
complete LEDGF/p75 cDNA.
4.2 Cell lines
LEDGF/p75-deficient cell lines. The human CD4+ T cell line -LEDGF/p75-deficient,
TL3 cells (32), were used for stable expression of LEDGF/p75 mutants. These cells
were generated by transduction of SupT1 cells with a HIV-derived vector expressing an
shRNA against LEDGF/p75. As control we used TC3 cells that were also derived by
transduction of SupT1 cells with a HIV-derived vector expressing a scrambled shRNA
sequence (32). TL3 cells express 97% less LEDGF/p75 mRNA than TC3 cells as
determined by real time PCR (32). To generate TL3 cells expressing different
LEDGF/p75 mutants, cells were transduced with a MLV-derived vector expressing the
LEDGF/p75 mutants (pJZ-LEDGF-FLAG) and selected in G418 (600µg /ml) as
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described previously (32). G418-resistant cell lines were obtained and characterized by
immunoblotting with an anti-LEDGF (BD Transduction Laboratories, catalog number
611714) or anti-FLAG monoclonal antibodies (Mabs) (Clone M2, Sigma). SupT1derived cell lines were grown in RPMI1640 while HEK293T-derived cells were grown in
DMEM and both culture mediums were supplemented with 10% of heat-inactivated fetal
calf serum, 2mM L-glutamine and 1% penicillin/streptomycin.
4.3 Generation of retroviral vectors
Procedures previously described (32) were followed for the production of the different
retroviruses used here. Briefly, MLV-derived vectors were produced in Phoenix A
packaging cells by calcium-phosphate co-transfection of 15µg of pJZLEDGF/p75 wild
type or pJZLEDGF/p75 mutants or pJZluc and 5µg of the Vesicular Stomatitis Virus
glycoprotein G (VSV-G) expression plasmid, pMD.G (from D. Trono). Forty-eight hrs
after transfection, the viral supernatants were harvested and concentrated by
ultracentrifugation at 124,750g for two hrs on a 20% sucrose cushion. HIV-derived
vectors expressing luciferase were produced by calcium-phosphate co-transfection of
HEK293T with 15µg of pHIVluc (32) and 5µg pMD.G. The viral-containing supernatant
was collected and concentrated by ultracentrifugation as described above. Viral
supernatant was collected forty-eight after transfection and aliquots stored at -80°C until
use.
4.4 Single-round viral infectivity assay.
TL3 cells and, TL3 cells expressing LEDGF/p75 WT or mutants were plated at 1x105
cells in 500µl of RPMI1640 culture medium in 24-well plates and infected with HIVluc
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viral supernatants. Four days post-infection, cells were collected by centrifugation at
1000g for six mins and the pellet resuspended in 200 µl of PBS. Half of the sample was
mixed with 100 µl of luciferase substrate (Bright-Glow™ Luciferase Assay System,
Promega) and the other half with 100 µl of cell viability substrate (CellTiter-Glo® Assay,
Promega). Cell lysates were incubated for 10 mins at room temperature in dark and
then luminescence measured in triplicate in 50 µl-samples using a microplate
luminometer reader.
4.5 Immunoblotting
Cellular lysates were resolved by SDS-PAGE and transferred overnight to PVDF
membranes at 100 mAmp at 4°C. Membranes were blocked in TBS containing 10%
milk for one hour and then incubated with the corresponding primary antibody diluted in
TBS-5% milk-0.05% Tween 20 (antibody dilution buffer). FLAG-tagged LEDGF/p75 was
detected with anti-FLAG Mab (1/500, M2, Sigma), non-tagged LEDGF/p75 was
detected with anti-LEDGF Mab (1/250). As loading control, anti-alpha tubulin Mab
(clone B-5-2, Sigma) was used at a 1/4000 dilution. Membranes were incubated
overnight at 4°C with anti-FLAG, and -LEDGF Mabs whereas anti-alpha tubulin Mab
were incubated for two hrs at 25°C. Primary antibody-bound membranes were washed
in TBS-0.1% Tween 20 and bound antibodies detected with goat anti-mouse Igs-HRP
(Sigma) diluted 1/2000 in antibody dilution buffer followed by chemoluminescence
detection. Levels of LEDGF/p75 4K were determined by densitometry analysis of
immunoblots using the gel analysis software UN-SCAN-IT gel 6.1 (Silkscientific).
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4.6 Integrase protection assay
LEDGF/p75-deficient HEK293T cells expressing Myc-tagged HIV integrase were
used to evaluate the effect of different LEDGF/p75 deletion mutants on integrase
protein stability. This assay is based on the integrase-binding-dependent capability of
LEDGF/p75 to protect integrase from proteasome-mediated degradation (30). Integrase
protein levels in these LEDGF/p75-deficient cells are very low, as detected by sensitive
immunoblottings, and the reexpression of the LEDGF/p75 WT rescues integrase levels
(30). Cells were plated at 0.45 X 106 cells per well in a six-well plate and transfected the
next day by calcium-phosphate co-transfection with 2 µg of pFLAG-LEDGF/p75 WT or
mutants. Forty-eight hours after transfection, cells were lysed in 300 µl of RIPA buffer
supplemented with protease inhibitors. Cell lysates were clarified by centrifugation at
22,000 X g for 3 min, and the supernatant was used for immunoblotting with anti-Myc or
anti-FLAG MAbs.
4.7 Integrase-to-chromatin tethering assay
This assay is based on the role of LEDGF/p75 in the chromatin tethering of HIV
integrase (34). Chromatin-bound LEDGF/p75 interacts with integrase through the IBD,
tethering the viral enzyme to chromatin during all the phases of the cell cycle.

In

LEDGF/p75-deficient cells, HIV integrase lacks its exclusively nuclear localization
during interphase and is not associated to chromatin during mitosis (34). 2LKD-INeGFP cells, lacking LEDGF/p75 and stably expressing HIV integrase-eGFP, were used
in this assay. Cells were plated at 2x105 cells in 2mls in a LabTek II chambered
coverglasses and transfected the next day with 2 µg of pFLAG-LEDGF/p75 wild type or
mutants. Eighteen hrs. after transfection fresh culture medium was added and forty	
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eight hours later cells were washed three times in PBS and fixed with 4% formaldehydePBS for 10 mins at 37°C. Then, cells were washed twice in PBS and stained with DAPI.
The subcellular distribution of HIV IN-eGFP-LEDGF/p75 complex was analyzed by
fluorescence microscopy.
4.8 Analysis of the HIV life cycle
106 TL3 and TL3-derived cells were infected with DNase-treated HIVluc. Twenty-four
hrs later 90% of the culture was harvested for DNA extraction (High pure PCR template
preparation kit, Roche) and the other 10% was cultured for another four days. At this
later time point cells were harvested and 106 cells used for DNA extraction while
0.5X106 cells were employed to determine luciferase activity and ATP levels.
DNA (20 ng) were used for the detection of total HIV cDNA, mitochondrial DNA and
2LTR circles while 50 ng of DNA were used for the Alu-LTR junctions PCR. Alu-LTR
and total HIV cDNA products were normalized for mitochondrial DNA and 2LTR circles,
respectively. All these real time PCRs were performed in a MiniOpticon system (Biorad) with primers and conditions previously described (32). Fold change was calculated
using the ΔΔCt method as recommended in the thermo-cycler manual and differences
were expressed in percentage, considering the value for TL3 LEDGF/p75 WT cells as
100%.
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5. RESULTS
5.1 Specific aim 1. To evaluate the role of SUMOylation in the HIV cofactor activity of
LEDGF/p75.
5.1.1

Generation

and

characterization

of

LEDGF/p75-deficient

cell

lines

expressing a SUMOylation-deficient LEDGF/p75 mutant (TL3 LEDGF/p75 4K).
Our laboratory recently discovered that LEDGF/p75 is SUMOylated at four different
lysine residues; K75, K250, K254 and K364 (5). To investigate whether or not this PTM
modifies the HIV-cofactor function of LEDGF/75, we generated a murine leukemia virus
(MLV)-derived

vector

expressing

a

C-terminally

FLAG

tagged

LEDGF/p75

SUMOylation-deficient mutant that has each of the Lysine SUMO target residues
mutated to Arginine (LEDGF/p75 4K). Using this plasmid we produced a MLV vector
and transduced LEDGF/p75-deficient cells (TL3 cells) that were selected in the
presence of G418. Expression of LEDGF/p75 4K was demonstrated by immunoblotting
with an anti-LEDGF specific antibody (Fig. 3B).
TL3 cells and TL3 cells stably expressing LEDGF/p75 WT, 4K, and a mutant lacking
the IBD (ΔIBD) were used as target cells in HIV single-round infectivity assays. The
non-replicating HIVluc vector was used in these experiments. This virus expresses
luciferase from the HIV promoter after integration. Therefore, luciferase levels in cells
challenged with HIVluc correlate with levels of viral infection. In all the single-round
infectivity assays described in this thesis the luciferase levels reported were normalized
to the intracelular levels of ATP of the infected cells analyzed. This procedure allows
normalizing the luciferase activity registered to the number of viable cells.
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As expected, low luciferase levels were detected in TL3 and TL3 LEDGF/p75 ΔIBD
cells as compared with TL3 LEDGF/p75 WT cells (Fig. 3A) indicating an impairment of
HIV infection. Importantly, TL3 LEDGF/p75 4K-1 cells also exhibited low levels of
luciferase activity. Quantification of multiple independent infection experiments indicated
that the HIV cofactor activity of LEDGF/p75 4K was two fold lower than the WT.

6
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Fold Infectivity
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3
2
1
0
LEDGF/p75
B
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ΔIBD
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kDa
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Figure 3. HIV cofactor activity of the SUMOylation deficient LEDGF/p75 mutant
K75R/K250R/K254R/K364R (4K). (A) LEDGF/p75 deficient human CD4+ T cells, TL3, and TL3
cells engineered to express LEDGF/p75 wild type (WT), a mutant lacking the integrase-binding
domain (ΔIBD), or a SUMOylation deficient mutant (4K) were challenged with a single-round
infection HIV reporter virus expressing luciferase and four days later luciferase levels were
measured. Standard deviations represent three independent experiments and the results are
representative of one cell line expressing LEDGF/p75 4K mutant (TL3 LEDGF/p75 4K-1). The
red line in the figure indicates the fold reduction observed with LEDGF/p75 ΔIBD. (B)
LEDGF/p75 expression in cells evaluated in panel A was determined by immunoblotting with an
anti-LEDGF antibody.
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To definitively prove the requirement of SUMOylation in the HIV cofactor activity of
LEDGF/p75 we generated three additional TL3-derived cell lines (4K-3, 4K-4, and 4K-7)
expressing a FLAG-tagged LEDGF/p75 4K mutant. The LEDGF/p75 4K expression on
these new cell lines was verified by immunoblotting using an anti-FLAG antibody (Fig.
4A). The levels of LEDGF/p75 4K were similar in cell lines 4K-1 (reported in figure 3)
and 4K-3, but were lower in cells lines 4K-4 and -7. Surprisingly, the susceptibility to
HIV infection was slightly higher in 4K-3 than in the control cell line expressing
LEDGF/p75 wild type (Fig. 4B). These findings completely differed form those reported
in figure 3 where the SUMOylation mutant exhibited two-fold less activity than the wild
type. Similarly to data reported with cell line 4K-1, cell lines 4K- 4 and -7 were less
susceptible to HIV infection (around two-fold less activity than the WT), however
densitometry analysis of the levels of expression of LEDGF/p75 mutant in cell lines 4K4 and -7 were also two-fold lower than in cell lines 4K-3 and -1.
Finally, a fourth cell line (TL3 LEDGF/p75 4K-8) expressing levels of LEDGF/p75 4K
similar to those observed in cell lines 4K-1 and -3 exhibited a slightly higher
susceptibility to HIV infection than the TL3 LEDGF/p75 WT cell line (Data not shown).
The above results indicated that the phenotype originally observed in TL3
LEDGF/p75 4K-1 was not confirmed by four independently generated cell lines and
therefore we conclude that LEDGF/p75 SUMOylation is not required for the HIV
cofactor activity of LEDGF/p75.
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Figure 4. HIV cofactor activity of LEDGF/p75 SUMOylation deficient cell lines; 4K-3, -4
and -7. (A) The LEDGF/p75 4K expression in cell lines used in panel B was measured by
immunobloting using an anti-FLAG antibody. The 4K-1 cell line used in figure 3 was also
included in this figure for comparison purposes. (B) Infectivity assay. The Data is representative
of three independent single-round infection experiments (n). The red line in the figure indicates
the infectivity levels observed TL3 cells.
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5.1.2 Mutation of SUMO acceptor sites in LEDGF/p75 does not affect the ability of
LEDGF/p75 to protect HIV integrase from proteasomal degradation.
Interaction of LEDGF/p75 with HIV integrase, protects this viral protein from
proteosomal degradation (30). Therefore, we evaluated if LEDGF/p75 SUMOylation
could influence this functional interaction. We performed an integrase protection assay
(18) to investigate the interaction of the LEDGF/p75 4K mutant with HIV integrase.
LEDGF/p75-deficient HEK293T cells stably expressing Myc-tagged HIV integrase (30)
were transiently transfected with plasmids expressing the LEDGF/p75 WT or the 4K
mutant, and the protein levels of integrase were evaluated by immunobloting 48 hrs
later. The LEDGF splice variant LEDGF/p52 known not to interact with HIV integrase
was used as a negative control.
The levels of integrase observed in LEDGF/p75-deficient cells, as expected (30),
were undetectable (Fig. 5). In contrast, when LEDGF/p75 was re-expressed the levels
of integrase notably increased. The same dramatic effect in the levels of integrase was
observed upon the expression of the LEDGF/p75 4K mutant (Fig. 5). However
LEDGF/p52 failed to augment integrase expression. Therefore, these data indicate that
SUMOylation is not required for LEDGF/p75 to interact with HIV integrase and protect it
from degradation. Moreover, these findings also correlate with the fact that LEDGF/p75
SUMOylation is not essential for its HIV cofactor activity (specific aim 1.1).
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Figure 5. Interaction of LEDGF/p75 4K mutant with HIV integrase. LEDGF/p75-deficient
HEK293T-derived cells stably expressing Myc-tagged HIV integrase (1) were transiently
transfected with plasmids expressing FLAG-tagged LEDGF/p52 (2), LEDGF/p75 WT (3), or 4K
mutant (4) and the levels of integrase evaluated by immunoblotting with anti-Myc antibody.
LEDGF proteins levels were determined in the same samples with anti-FLAG antibody. Levels
of endogenous Myc protein were used as loading control.

	
  
	
  
	
  

24	
  
	
  

	
  
	
  
5.1.3 Mutation of SUMOylation target sites does not affect the ability of
LEDGF/p75 to tether HIV integrase to the host chromatin.
The ability of LEDGF/p75 to tether HIV integrase to the host chromatin is essential for
HIV DNA integration. In order to evaluate whether or not SUMOylation is required for
the capacity of LEDGF/p75 to tether HIV integrase to the chromatin, we implemented
the integrase-to-chromatin-tethering assay (18). LEDGF/p75 deficient cells expressing
HIV integrase-EGFP (2LKD-IN-eGFP cells) were transfected with the LEDGF/p75 WT,
ΔIBD, or 4K mutants. We next analyzed the subcellular localization of integrase by
confocal microscopy analysis. Expectedly, our analysis showed a pancellular
localization of HIV integrase on 2LKD-IN-eGFP cells either during interphase or in
mitosis (Fig. 6). The same integrase distribution was detected for the LEDGF/p75 ΔIBD
mutant (Fig. 6). However a different integrase subcellular localization was seen upon
the re-expression of LEDGF/p75 WT or the LEDGF/p75 SUMOylation mutant. The viral
protein was found to be associated to the chromatin during cell division and remaining
in the cell nuclei during interphase. Similarly, the transient transfection of the
LEDGF/p75 4K mutant in 2LKD-IN-eGFP cells showed identical integrase-eGFP cellular
localization to the one observed in the WT (Fig. 6). Thus, these results demonstrated
that SUMOylation is not required for the ability of LEDGF/p75 to tether HIV integrase to
the host chromatin or to interact with HIV integrase and protect it from proteasomal
degradation (specific aim 1.2), therefore supporting the non-essential role of
LEDGF/p75 SUMOylation on its HIV cofactor activity (specific aim 1.1).
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Figure 6. Interaction of LEDGF/p75 4K mutant with HIV integrase and the host chromatin.
LEDGF/p75-deficient HEK293T-derived cells stably expressing eGFP-tagged HIV integrase
were transiently transfected with plasmids expressing FLAG-tagged LEDGF/p75 WT, IBD
deletion, or 4K mutants and the subcellular distribution of eGFP-integrase determined by
confocal microscopy.
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5.2 Specific aim 2. To determine the role of CR1 phosphorylated residues in the HIV
cofactor activity of LEDGF/p75.
5.2.1 Mutation of phosphorylation target sites of LEDGF/p75 CR1 region.
To verify the previously reported role of CR1 (18) (Fig. 1) in the HIV co-factor activity
of LEDGF/p75, we generated a new TL3-derived cell line expressing a LEDGF/p75
ΔCR1 mutant. The expression of the mutant protein was evaluated by immunoblotting
(Fig. 7A) and these cells were used in single-round infection assays.
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Figure 7. Role of the CR1 region in the HIV cofactor activity of LEDGF/p75. (A)
LEDGF/p75 expression was verified in the cell lines studied by immunoblotting with an antiLEDGF antibody. (B) Single-round infection assay. LEDGF/p75-deficient cells (TL3) and TL3
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cells engineered to express LEDGF/p75 wild type (WT), or LEDGF/p75 mutants lacking the
integrase-binding domain (ΔIBD), or the CR1 region (ΔCR1) were infected with HIVluc and five
days later luciferase levels were measured. Data is representative of multiple infection
experiments (n). The red line represents the fold reduction in infectivity observed in TL3
LEDGF/p75 ΔIBD.

In support to previous observations (18), the HIV cofactor activity of LEDGF/p75
ΔCR1 was significantly impaired (Fig. 7B) showing a three-fold reduction in activity as
compare to LEDGF/p75 WT. In order to determine protein motifs within the CR1 region
(residues 94 – 145) implicated in the HIV cofactor activity of LEDGF/p75 we focused in
a cluster of phosphosites reported to occur in human and mouse LEDGF/p75 in several
global phosphoproteomic analyses (4, 17, 39, 46, 50, 52). CR1 contains a cluster of
nine pS/pT residues (Fig. 8). Clusters of pS/pT have been identified in many
phosphorylated proteins (56); therefore they are considered elementary building blocks
in phosphorylation regulation. As in many other proteins, the CR1 pS/pT cluster is
predicted to show coordination and positional dependency. It has been postulated that
pS/pT clusters may increase the effectiveness of the phosphorylation-dependent
response (56). The CR1 pS/pT cluster is formed by two discrete subsets that are
predicted to functionally interact. pT141 is contained in a predicted forkhead-associated
domain (FHA) interaction motif (residues 141–144). The FHA domain is a protein
module involved in signaling, cell cycle control and DNA repair. This domain binds to
specific pT-containing sequences (42). Therefore, it is likely that this LEDGF/p75
phosphosite (pT141) is implicated in protein-protein interactions. In addition, FHA in
LEDGF/p75 is predicted to act as a conditional docking site for Polo-like kinase-1
(PLK1). PLK1 has a polo-box domain (PBD) that interacts with phosphorylated
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substrates and is predicted to bind to residues 140–143 within CR1. This PBD binding
site is located within a proline-directed kinase target site (residues 138–144) suggesting
that it could be phosphorylated by this kinase. Phosphorylation of the PBD binding site
would recruit PLK1 to LEDGF/p75 that in turn would generate pT115/pS116/pS118 in
CR1.

Figure 8. Phospho-regulatory network in the CR1 region. Phosphosites are indicated in bold
and bigger font characters, predicted motifs are underlined. Postulated interactions between
phosphosites are indicated by arrows. Reffer to the text for more details.

To evaluate the function of these phosphosites we developed TL3-derived cell lines
expressing LEDGF/p75 mutants in which the serine or threonine residues targeted by
phosphorylation were changed to alanine residues. Mutations were designed to destroy
the regulatory mechanisms described above. These mutations included, T141A
(Proline-directed kinase predicted target), T115A/S116A/S118A (PLK1 predicted
target), and S105A/S106A (CK1 target site). The expression levels of these mutants
were verified by immunobloting (Fig. 9A) and the engineered cells used in single-round
infection assays (Fig. 9B). Mutations targeting the described phosphosites did not
reduce the HIV cofactor activity of LEDGF/p75 to the levels observed with the mutant
lacking the entire CR1 region. In fact, the increase in susceptibility to HIV infection of
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TL3

cells

expressing

these

mutants

was

similar

(T115A/S116A/S118A

and

S105A/S106A) or even higher (T141A) than the typical increase observed with TL3
LEDGF/p75 WT cells (7-9 folds more infectable than TL3 cells). Therefore data in figure
9B indicate that the targeted phosphosites are not implicated in the role of CR1 in the
HIV cofactor activity of LEDGF/p75.
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Figure 9. Implication of CR1 phosphorylation sites in the HIV cofactor activity of
LEDGF/p75. (A) Expression of LEDGF/p75 CR1 phosphorylation mutants in TL3 cells
evaluated by immunoblotting with an anti-LEDGF antibody. (B) LEDGF/p75-deficient cells, and
TL3 cells engineered to express LEDGF/p75 mutants lacking IBD (ΔIBD), CR1 (ΔCR1), or
mutated at CR1 phosphorylation sites (S105A/S106A, T115A/S116A/S118A and T141A) were
challenged with HIVluc and five days later luciferase levels were evaluated. Data are
representative for multiple single-round infection assays (n). The red line indicates the infectivity
levels detected in TL3 LEDGF/p75 ΔIBD.
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5.2.2 HIV-1 DNA integration is severely impaired in LEDGF/p75-deficient cells
expressing a LEDGF/p75 ΔCR1 mutant.
To further characterize the role of the CR1 region of LEDGF/p75 in HIV infection we
determined the step of the viral life cycle affected in cells expressing this mutant. This
approach allowed determining whether or not CR1 is involved in viral DNA integration
and/or in other steps of the HIV replication cycle.
TL3, TL3 LEDGF/p75 WT, and TL3 LEDGF/p75 ΔCR1 cell lines were infected with
DNAse-treated HIVluc virus and one day later cellular DNA was isolated from a fraction
of the culture (90%) while the rest of the cells were kept in culture for four days more. At
this later time point, cells were used for DNA extraction and for quantifying luciferase
activity. The DNA isolated at 24 hrs post-infection was used to measure mitochondrial
DNA, HIV-gag-DNA (total HIV DNA), and 2-LTR circles using quantitative real-time
PCR. Similarly, the DNA harvested 5 days after infection was used to determine levels
of mitochondrial DNA, HIV-gag-DNA and Alu-LTR junctions. Levels of mitochondrial
DNA were determined as a loading control to ensure that same amounts of similar
quality DNA is harvested from each of the studied cell lines.

Total HIV DNA is a

measurement of the efficiency of reverse transcription and the stability of the HIV cDNA.
2LTRs are circular forms of HIV cDNA that do not produce infectious progeny (36).
2LTR circles are only formed in the nucleus from unintegrated linear HIV DNA, therefore
their levels indirectly correlate with the efficiency of viral DNA integration and directly
correlate with the effectiveness of the nuclear import of the pre-integration complex.
Levels of Alu-LTR junctions directly correlate with the viral DNA integration efficiency.
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As it was previously described (8), we found that HIV integration in cells defective for

Fold change

LEDGF/p75 was significantly impaired as indicated by the low Alu-LTR levels (Fig. 10).
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Figure 10. Real time PCR analysis of the HIV viral life cycle in LEDGF/p75-deficient cells
that express a LEDGF/p75 ΔCR1 mutant. Levels of 2LTR circles and total HIV DNA
measured one day after HIV infection were normalized to the levels of mitochondrial DNA.
Levels of Alu-LTR junctions were determined in the same cells but five days after infection and
were also normalized to the levels of mitochondrial DNA. Wild type levels were considered as
reference. The blue line indicates the levels of different HIV cDNA products detected in TL3
LEDGF/p75 WT cells. Data representative for one independent experiment.
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Moreover, HIV-integration was rescued upon re-expression of the LEDGF/p75 WT,
showing a significant increase in Alu-LTR levels (Fig. 10). Importantly, the Alu-LTR
levels of the LEDGF/p75 ΔCR1 mutant were found to be notably low, comparable to
those found in TL3 cells, indicating that HIV DNA integration is severely defective in the
TL3 cells expressing LEDGF/p75 ΔCR1. These data indicate a role for the LEDGF/p75
CR1 region in the DNA integration step of HIV.
To characterize additional steps on the HIV replication cycle, levels of 2-LTR circles
and total HIV DNA (gag DNA) were measured in DNA extracted one day post infection.
No significant changes were seen for the levels of total HIV cDNA or 2-LTR circles in
cells expressing the LEDGF/p75 WT or the CR1 mutant (Fig.10), indicating that neither
reverse transcription nor nuclear import were affected in TL3 LEDGF/p75 ΔCR1 cells.
5.3 Specific aim 3. To define the role of the CR6 region in the HIV cofactor activity of
LEDGF/p75.
The role in HIV infection of several solvent exposed evolutionary conserved regions
(CR regions) in LEDGF/p75 has been systematically investigated (18). However, the
implication of the C-terminal end (residues 478-497) of LEDGF/p75 on its HIV cofactor
activity has not been evaluated yet (Fig. 1). The LEDGF/p75 CR6 region resembles a
protein motif found in several transcription factors that is implicated in protein-protein
interactions [polar zipper (16)].
5.3.1 Stably expression of LEDGF/p75 ΔCR6 in LEDGF/p75-deficient cells.
In order to investigate the influence of the LEDGF/p75 CR6 region on its HIV
cofactor activity we expressed in TL3 cells a deletion mutant lacking this entire region
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(ΔCR6). The cDNA encoding this flag-tagged mutant was cloned into an MLV-derived
expression vector and the LEDGF/p75 open reading frame was fully sequenced. This
viral vector was used to express the LEDGF/p75 mutant in LEDGF/p75-deficient TL3
cells. The expression of LEDGF/p75 ΔCR6 cell line was confirmed by western blotting
using an anti-LEDGF antibody (Fig. 11A).
The TL3 LEDGF/p75 ΔCR6 cell line was used as target for single-round infection
assays using an HIV-derived virus expressing luciferase (Fig. 11B). Infectivity of TL3
cells was rescued by expression of the LEDGF/p75 ΔCR6 mutant to levels (six-fold
higher than TL3 cells) that are similar to those typically found in TL3 expressing
LEDGF/p75 WT (7-9 folds more infectable than TL3 cells). In addition, infectivity of TL3
LEDGF/p75 ΔCR6 cells was significantly higher than those determined in parallel
experiments in TL3 and TL3 cells expressing LEDGF/p75 mutants (ΔIBD and ΔCR1)
known to be impaired in their HIV cofactor activity. Therefore, these data indicated that
CR6 is not implicated in the role of LEDGF/p75 in HIV DNA integration.
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Figure 11. Role of the CR6 region of LEDGF/p75 in its HIV cofactor activity. (A)
LEDGF/p75 levels in the different TL3-derived cells lines were verified by immunoblotting with
an anti-LEDGF antibody. (B) LEDGF/p75-deficient cells (TL3 cells) and TL3 cells stably
expressing LEDGF/p75 ΔIBD, ΔCR1, or ΔCR6 mutants were challenged with HIVluc and five
days later luciferase levels were quantified. Data represent results from multiple independent
infection experiments (n). The red line indicates the infectivity levels detected in TL3
LEDGF/p75 ΔIBD.
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6. DISCUSSION
	
  
Unpublished experiments from our laboratory indicated that E3 SUMO ligases that
interact with LEDGF/p75, a SUMOylation target, are implicated in HIV infection (Fig. 2).
These data prompted us to evaluate whether or not LEDGF/p75 SUMOylation was
required for its HIV cofactor activity.
Initially we observed reduced HIV susceptibility in a LEDGF/p75-deficient cell line
expressing a LEDGF/p75 SUMOylation mutant (TL3 LEDGF/p75 4K-1). However, this
defective phenotype was not revealed in two other independently derived cell lines (TL3
LEDGF/p75 4K-3 and -8) that express levels of LEDGF/p75 mutant similar to those
found in TL3 LEDGF/p75 4K-1. Reduced infectivity was again observed in two other cell
lines but probably because they also expressed lower levels of LEDGF/p75 4K.
Therefore, we concluded that SUMOylation of LEDGF/p75 is not required for its HIV
cofactor activity. We believe that the defective phenotype initially observed (TL3
LEDGF/p75 4K-1) was due to a clonal variation effect. It is possible that during G418
selection cells defective for viral infection, in a LEDGF/p75-independent manner,
randomly and inadvertently outgrow constituting the majority of the population of the cell
line TL3 LEDGF/p74 4K-1. This random selection event did not occur during the
generation of the other cell lines studied. Our results strongly encourage to evaluate any
found phenotype with more that one independent derived cell lines to avoid the effect of
clonal variation.
In support of a dispensable role of SUMOylation in the HIV cofactor activity of
LEDGF/p75, mutations impairing LEDGF/p75 SUMOylation did not affect the ability of
this protein to interact with HIV integrase and protect the viral enzyme from proteosomal
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degradation or to tether integrase to the host chromatin. These are functions of
LEDGF/p75 required for its HIV cofactor activity.
In addition, the fact that SUMOylation is not required for the HIV cofactor activity of
LEDGF/p75 suggests that the observed effects of PIAS1 or 4 deficiencies on HIV
infection are LEDGF/p75-independent.
It is important to point out, however, that our data do not formally exclude the
possibility that SUMOylation of LEDGF/p75 impairs its cofactor role. SUMOylation of
LEDGF/p75 at the PWWP or IBD could impair the HIV cofactor activity of LEDGF/p75
by affecting its interaction with the chromatin or the integrase, respectively. According to
the crystal structure of these protein domains, the SUMO acceptor residues are located
in very close proximity to the residues implicated in chromatin binding (PWWP domain)
or integrase binding (IBD). Therefore, following the attachment of a SUMO protein or a
chain of SUMO proteins to LEDGF/p75, esteric hindrance could prevent the interaction
of LEDGF/p75 with chromatin or integrase, affecting in this way its HIV cofactor role.
In this thesis, we also characterized in more details the role of the CR1 region of
LEDGF/p75 in HIV infection. Results obtained from two independently derived cell lines
confirmed an important role for CR1 in the LEDGF/p75 HIV cofactor activity. Studies
evaluating HIV life cycle also demonstrated, for first time, that the CR1 region has an
important role in the activity of LEDGF/p75 in HIV DNA integration.
Importantly previous studies indicated that deletion of CR1 does not affect the ability
of LEDGF/p75 to interact with integrase and to tether the viral enzyme to chromatin
(18). It has been demonstrated that upon LEDGF/p75 interaction integrase promotes an
stronger binding of the LEDGF/p75-integrase complex to the chromatin. This enhanced
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chromatin binding is critical in the HIV cofactor activity of LEDGF/p75 mutants with a
defective interaction with the host chromatin, but its role in the chromatin-bound
LEDGF/p75 is unknown (2). More recently, in collaboration with an undergraduate
student in the laboratory, I demonstrated that CR1 is neither required for the integraseinduced enhanced chromatin binding activity of the LEDGF/p75-integrase complex.
Therefore, the role of CR1 in HIV DNA integration is independent of the integrasechromatin tethering mechanism of LEDGF/p75. Potentially, CR1 could be implicated in
the interaction of LEDGF/p75 with other cellular proteins that promotes HIV DNA
integration.
Our data additionally revealed that the role of CR1 in the HIV cofactor activity of the
LEDGF/p75 is not regulated by phosphorylation of a cluster of evolutionary conserved
Ser/Thr residues present in this region. Nonetheless, it is relevant to mention that
although the LEDGF/p75 CR1 T141A phosphorylation mutant did not reduce the HIV
cofactor activity of LEDGF/p75, and apparently having no role in this function, it is
possible that the preceding threonine residue (T140) could be substituting the function
of the mutated threonine (T141A) preserving in this way phosphorylation at this region.
This would conserve the functionality of the predicted domains in this region. For
instance, it is possible that the predicted forkhead-associated domain interaction motif
(residues 141-144) recruits cellular proteins involved in DNA repair that could be
favoring HIV DNA integration. The polo-box domain included in this CR1 region
(residues 140-143) could also be involved in HIV infection, since it is predicted to be a
binding site for the Polo-like kinase-1 that is known to be involved in cell cycle regulation
and in protein phosphorylation. Lastly, the proline-directed kinase target site (residues
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138–144) could also be recruiting this kinase to phosphorylate T140, upon CR1 T141A
mutation, this way replacing the important function of the T141 in the functionality of the
previously mentioned domains. This possibility was not studied in this thesis; however
we plan to further evaluate the HIV cofactor activity of the LEDGF/p75 T140A, T141A
mutant to verify this premise. Therefore, we expect that the double mutation T140A,
T141A will abrogate the function of this protein motif.
In addition, our data indicated that the HIV cofactor activity of the LEDGF/p75 T141A
mutant was two-fold higher than the wild type suggesting that T141 phosphosite could
negatively regulate the HIV cofactor activity of LEDGF/p75. This potential function
deserves further evaluation. Similarly, it is intended to continue examining CR1 to find
key amino acid residues that are involved in its contribution to the LEDGF/p75 HIV
cofactor role. It has been pondered generating smaller deletion mutants within the CR1
region to locate the protein motif responsible for this function.
The better understanding of the role of CR1 in HIV-DNA integration is important
considering the possibility of generating new drugs that block the LEDGF/p75 HIV
cofactor activity to prevent HIV-DNA integration. And, despite of the increased number
of new therapeutic drugs that have emerged recently to inhibit HIV-DNA integration it is
important to continue the development of effective drugs that counteract the rapid
resistance of HIV to different treatments.
Finally, two independently generated LEDGF/p75 CR6 deletion mutants proved that
this evolutionary conserved region in LEDGF/p75 does not cooperate in its HIV cofactor
role.
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7. CONCLUSION
Specific aim 1. To evaluate the role of SUMOylation in the HIV cofactor activity of
LEDGF/p75.
We demonstrated that SUMOylation is neither required for the HIV cofactor activity of
LEDGF/p75 nor for its interaction with HIV integrase or for tethering integrase to the
host chromatin. We have also shown the significance of verifying identified phenotypes
with more than one independently derived cell line to avoid clonal variation effects that
could lead to wrong interpretations.
Specific aim 2. To determine the role of CR1 phosphorylated residues in the HIV
cofactor activity of LEDGF/p75.
We have demonstrated a relevant role of the CR1 region of LEDGF/p75 in HIV DNA
integration by:
1. Showing the implication of CR1 in HIV infection with cell lines generated
independently from the one reported in a previous study (18). These evidences
demonstrated that the requirement of CR1 is real and not due to a clonal
variation effect observed in the only cell line previously reported.
2. Demonstrating for the first time that HIV DNA integration is severely defective in
LEDGF/p75-deficient cells engineered to express LEDGF/p75 ΔCR1.
Our studies, reported here, have also excluded the participation of evolutionarily
conserved phosphosites within CR1 on the HIV cofactor activity of LEDGF/p75.
Specific aim 3. To define the role of the CR6 region in the HIV cofactor activity of
LEDGF/p75.
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We have demonstrated that the unexplored and evolutionary conserved CR6 region
of LEDGF/p75 is not required for its HIV cofactor activity.
In summary, this work have brought further evidences of the existence of integrasechromatin tethering independent mechanisms in the HIV cofactor activity of LEDGF/p75
by demonstrating an important role of CR1 in HIV DNA integration.
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